16.76
price up icon2.07%   0.34
after-market アフターアワーズ: 16.76
loading
前日終値:
$16.42
開ける:
$16.42
24時間の取引高:
293.43K
Relative Volume:
1.02
時価総額:
$885.03M
収益:
-
当期純損益:
$-69.13M
株価収益率:
-13.97
EPS:
-1.2
ネットキャッシュフロー:
$-50.91M
1週間 パフォーマンス:
-0.89%
1か月 パフォーマンス:
-23.96%
6か月 パフォーマンス:
-6.11%
1年 パフォーマンス:
+23.42%
1日の値動き範囲:
Value
$15.95
$16.85
1週間の範囲:
Value
$15.28
$17.26
52週間の値動き範囲:
Value
$10.60
$29.60

Tyra Biosciences Inc Stock (TYRA) Company Profile

Name
名前
Tyra Biosciences Inc
Name
セクター
Healthcare (1182)
Name
電話
(619) 728-4760
Name
住所
2656 STATE STREET, CARLSBAD
Name
職員
38
Name
Twitter
Name
次回の収益日
2024-08-08
Name
最新のSEC提出書
Name
TYRA's Discussions on Twitter

Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-06-30 開始されました Wedbush Outperform
2023-02-03 開始されました Oppenheimer Outperform
2022-06-23 開始されました H.C. Wainwright Buy
2022-03-08 アップグレード Jefferies Hold → Buy
2021-11-08 ダウングレード Jefferies Buy → Hold
2021-10-11 開始されました BofA Securities Buy
2021-10-11 開始されました Cowen Outperform
2021-10-11 開始されました Jefferies Buy
すべてを表示

Tyra Biosciences Inc (TYRA) 最新ニュース

pulisher
09:00 AM

Auour Investments LLC Reduces Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat

09:00 AM
pulisher
Nov 04, 2024

Long Term Trading Analysis for (TYRA) - Stock Traders Daily

Nov 04, 2024
pulisher
Nov 04, 2024

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up Following Insider Buying Activity - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Tyra Biosciences director Nina Kjellson sells $2.28m in stock By Investing.com - Investing.com Australia

Nov 02, 2024
pulisher
Nov 02, 2024

Tyra Biosciences director Nina Kjellson sells $2.28m in stock - Investing.com

Nov 02, 2024
pulisher
Nov 01, 2024

Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Purchases $152,000.00 in Stock - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock By Investing.com - Investing.com UK

Nov 01, 2024
pulisher
Oct 29, 2024

Tyra Biosciences (NASDAQ:TYRA) Trading Down 10.2%Here's What Happened - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment By Investing.com - Investing.com Australia

Oct 29, 2024
pulisher
Oct 29, 2024

Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Piper Sandler maintains Overweight on Tyra Biosciences stock By Investing.com - Investing.com Canada

Oct 29, 2024
pulisher
Oct 28, 2024

Tyra Biosciences stock target lifted, retains buy on clinical trial data - Investing.com Canada

Oct 28, 2024
pulisher
Oct 28, 2024

Tyra Biosciences (NASDAQ:TYRA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

FDA clears Tyra Biosciences' trial for dwarfism drug By Investing.com - Investing.com Australia

Oct 28, 2024
pulisher
Oct 28, 2024

Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $32.00 at HC Wainwright - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

FDA clears Tyra Biosciences' trial for dwarfism drug - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PR Newswire

Oct 28, 2024
pulisher
Oct 25, 2024

Tyra Biosciences (NASDAQ:TYRA) Shares Gap DownWhat's Next? - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Tyra Biosciences' (TYRA) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga

Oct 25, 2024
pulisher
Oct 25, 2024

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer - Marketscreener.com

Oct 25, 2024
pulisher
Oct 25, 2024

(TYRA) Long Term Investment Analysis - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 24, 2024

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PR Newswire

Oct 24, 2024
pulisher
Oct 24, 2024

Tyra Biosciences Reports Interim Clinical Proof-Of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer - Marketscreener.com

Oct 24, 2024
pulisher
Oct 23, 2024

Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet - MSN

Oct 23, 2024
pulisher
Oct 23, 2024

Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week HighWhat's Next? - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - Marketscreener.com

Oct 23, 2024
pulisher
Oct 23, 2024

Tyra Biosciences stock soars to 52-week high of $28.86 - Investing.com India

Oct 23, 2024
pulisher
Oct 23, 2024

Tyra Biosciences stock soars to 52-week high of $28.86 By Investing.com - Investing.com South Africa

Oct 23, 2024
pulisher
Oct 22, 2024

RA Capital Management, L.P. Reduces Stake in Tyra Biosciences Inc - Yahoo Finance

Oct 22, 2024
pulisher
Oct 22, 2024

Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 19,084 Shares of Stock - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

Tyra Biosciences (NASDAQ:TYRA) Shares Up 4.2%Here's Why - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Simply Wall St

Oct 21, 2024
pulisher
Oct 21, 2024

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point - Seeking Alpha

Oct 21, 2024
pulisher
Oct 20, 2024

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation - Yahoo Finance

Oct 20, 2024
pulisher
Oct 20, 2024

Tyra Biosciences issues warrants in exchange for common stock - Investing.com India

Oct 20, 2024
pulisher
Oct 18, 2024

Tyra Biosciences issues warrants in exchange for common stock By Investing.com - Investing.com UK

Oct 18, 2024
pulisher
Oct 18, 2024

Tyra raised to buy by BofA ahead of TYRA-300 data readout (NASDAQ:TYRA) - Seeking Alpha

Oct 18, 2024
pulisher
Oct 18, 2024

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - MSN

Oct 18, 2024
pulisher
Oct 18, 2024

Tyra Biosciences (NASDAQ:TYRA) Upgraded by Bank of America to Buy - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

BofA upgrades Tyra Biosciences shares rating to Buy, raises price target - Investing.com Canada

Oct 18, 2024
pulisher
Oct 18, 2024

Tyra Biosciences stock soars to 52-week high of $25.3 By Investing.com - Investing.com Australia

Oct 18, 2024
pulisher
Oct 17, 2024

Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 10,035 Shares of Stock - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Tyra Biosciences CEO Harris Todd sells $1.5 million in stock By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Tyra Biosciences CEO Harris Todd sells $1.5 million in stock - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Tyra Biosciences To Present Initial SURF301 Study Results At The ENA Symposium Next Week - RTTNews

Oct 17, 2024
pulisher
Oct 16, 2024

Tyra Biosciences (NASDAQ:TYRA) Hits New 1-Year HighHere's What Happened - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Tyra Biosciences stock soars to 52-week high of $25.3 - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc - Yahoo Finance

Oct 16, 2024

Tyra Biosciences Inc (TYRA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Tyra Biosciences Inc (TYRA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Kjellson Nina S
Director
Nov 01 '24
Sale
16.56
27,493
455,272
458,506
Kjellson Nina S
Director
Oct 30 '24
Sale
16.17
11,078
179,120
472,207
Fuhrman Alan
Chief Financial Officer
Oct 30 '24
Buy
16.00
9,500
151,954
12,849
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):